New Brunswick, N.J., December 07, 2021 – Physician-scientists from Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, will present expansive new hematology/oncology data from their clinical research program at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, being held in Atlanta, Georgia (and virtually) from December 11-14, 2021. A total of 31 abstracts have been accepted, with data focusing on the latest surgical and treatment advancements in blood cancers, including pediatric hematology, leukemia, lymphoma and myeloma. Rutgers Cancer Institute, in partnership with RWJBarnabas Health, is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center.
“Our dynamic teams of nationally renowned cancer specialists and researchers have a deep and ongoing commitment to innovative research in blood cancers, which we proudly look forward to demonstrating through our vast lineup of data at this year’s ASH Annual Meeting and Exposition,” said Andrew M. Evens, DO, MSc, FACP , Associate Director for Clinical Services, Rutgers Cancer Institute; System Director of Medical Oncology and Oncology Lead for Combined Medical Group, RWJBarnabas Health, who is also an attending physician at Robert Wood Johnson University Hospital. “RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, is dedicated to advancing cancer treatments, patient care and ultimately, transforming patient outcomes, with the goal of one day eradicating the disease,” adds Dr. Evens, who is also Associate Vice Chancellor, Clinical Innovation and Data Analytics, at Rutgers Biomedical and Health Sciences.
Highlights of the accepted abstracts include the following:
- Current NCCN guidelines recommend 1 of 3 first-line regimens for stage III or IV classical Hodgkin lymphoma (cHL). Data from CONNECT, the first real-world observational survey of physicians, patients and caregivers in cHL was designed to understand the decision-making process when selecting a first-line cHL treatment regimen for stage III or IV cHL, and gain insights into physicians’ preferred regimens and factors that influence their treatment choices.
- Data from a large multicenter real-world evidence analysis of autoimmune (AI) diseases and lymphoma examining the impact of AI diseases on patient outcome across varying lymphoma subtypes, including the role of immunosuppressive medications.
- Data from a large retrospective real-world evidence study of newly-diagnosed Primary Central Nervous System Lymphoma (PCNSL) patients. Treatment of older patients with PCNSL is challenging due to the prevalence of comorbidities, frailty and complexities with effective delivery of chemotherapy. This study analyzed post-induction treatment patterns and outcomes across 20 U.S. academic centers.
- Research that revealed Sirt1 as a novel therapeutic target in T-cell Acute Lymphoblastic Leukemia (T-ALL). T-ALL is an aggressive hematological malignancy that affects both children and adults, and 20%-50% of patients show primary resistance or relapse after treatment, and ultimately die from their disease.
The full list of presentations at this year’s ASH Annual Meeting and Exposition follows:
Oral Presentations |
||
|
Abstract and Session No. |
Title |
Presentation Date/Time |
| Abstract 50 (Session 627) |
A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication |
Saturday, December 11, 2021, at 9:45 a.m. EST |
| (Session 905) | Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry |
Saturday, December 11, 2021, at 10 a.m. EST |
| Abstract 184 (Session 905) |
A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy |
Saturday, December 11, 2021, at 12:45 p.m. EST |
| Abstract 160 (Session 653) | Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) |
Saturday, December 11, 2021, at 12:45 p.m. EST |
|
Abstract 231 (Session 624) |
Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis |
Saturday, December 11, 2021, at 2:30 p.m. EST |
|
Abstract 323 |
PI3-Kinase Deletion Dysregulates Autophagy in HSCs and Promotes Myelodysplasia |
Saturday, December 11, 2021, at 5:00 p.m. EST |
|
Abstract 357 |
Pervasive Hypermutation of Super-Enhancer Regions Dysregulates Oncogene Expression in Diffuse Large B-Cell Lymphoma |
Sunday, December 12, 2021, at 10:00 a.m. EST |
|
Abstract 455 (Session 627) |
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers |
Sunday, December 12, 2021, at 1 p.m. EST |
|
Abstract 532 (Session 627) |
Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices |
Sunday, December 12, 2021, at 5:15 p.m. EST |
|
Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Mitochondrial Survival Pathways |
Monday, December 13, 2021, at 2:45-4:15 p.m. EST |
|
|
Abstract 814 (Session 623) |
Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403) |
Monday, December 13, 2021, at 5:15 p.m. EST |
|
Abstract 878 (Session 624) |
Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant |
Monday, December 13, 2021, at 6:30 p.m. EST |
|
Abstract 884 (Session 627) |
Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy |
Monday, December 13, 2021, at 6:30 p.m. EST |
|
Abstract 879 |
Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data |
Monday, December 13, 2021, at 6:45 p.m. EST |
|
Abstract 917 |
Grapes: Trivia Game Increases Sickle Cell Disease Knowledge in Patients and Providers and Mitigates Health Biases |
Monday, December 13, 2021, at 7:15 p.m. EST |
|
Poster Presentations |
||
|
Abstract and Session No. |
Title |
Presentation Date/Time |
|
Abstract 1460 (Session 627) |
Connect® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study |
Saturday, December 11, 2021, at 10 a.m. EST |
|
Abstract 1390 (Session 624) |
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens |
Saturday, December 11, 2021, 5:30-7:30 p.m. EST |
|
Abstract 1966 (Session 905) |
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age |
Saturday, December 11, 2021, 5:30-7:30 p.m. EST |
|
Abstract 1428 (Session 627) |
Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Real World Evidence (RWE) of Prognostication and Outcomes with Post-Induction Therapy |
Saturday, December 11, 2021, 5:30-7:30 p.m. EST |
|
Abstract 1347 |
Production of Anti-Spike Antibodies in Response to COVID Vaccine in Lymphoma Patients |
Saturday, December 11, 2021, at 5:30-7:30 p.m. EST |
|
Abstract 1491 |
Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia |
Saturday, December 11, 2021, at 5:30-7:30 p.m. EST |
|
Abstract 2213 (Session 602) |
The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas |
Sunday, December 12, 2021, 6-8 p.m. EST |
|
Abstract 2403 (Session 621) |
ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis |
Sunday, December 12, 2021, 6-8 p.m. EST |
|
Abstract 2457 (Session 624) |
A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy |
Sunday, December 12, 2021, 6-8 p.m. EST |
|
Abstract 2467 (Session 624) |
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma |
Sunday, December 12, 2021, 6-8 p.m. EST |
|
Abstract 2221 (Session 603) |
Sirt1 Is a Novel Therapeutic Target in T-ALL |
Sunday, December 12, 2021, 6-8 p.m. EST |
|
Abstract 3853 (Session 704) |
Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) |
Monday, December 13, 2021, 6-8 p.m. EST |
|
Abstract 3407 (Session 614) |
Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152 |
Monday, December 13, 2021, 6-8 p.m. EST |
|
Abstract 3396 (Session 614) |
Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium |
Monday, December 13, 2021, 6-8 p.m. EST |
|
Abstract 3485 |
Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001 |
Monday, December 13, 2021, 6-8 p.m. EST |
|
Abstract 3100 |
Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study |
Monday, December 13, 2021, 6-8 p.m. EST |
About Rutgers Cancer Institute of New Jersey
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
For journalists – contact:
Krista Didzbalis
Media Relations Assistant
908-812-6114
krista.didzbalis@rutgers.edu
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)